Top 7 GMP Audit Failures in South African Pharma Companies (and How to Prevent Them)

At the centre of these inspections lies Good Manufacturing Practice (GMP). GMP ensures that products are consistently produced and controlled according to quality standards, safeguarding patient safety and product integrity. But many South African facilities continue to stumble during GMP audits. These failures lead to corrective action demands, licence delays, reputational harm, and in some cases, suspension of operations.

This article explores the seven most common GMP audit failures in South Africa, their underlying causes, and practical strategies companies can adopt to prevent them. While the lessons are universal, the emphasis here is on the realities of South Africa’s regulatory and resource environment.

1. Incomplete or Poorly Maintained Documentation

Why it matters: GMP compliance is inseparable from documentation. Regulators often repeat the phrase, “If it isn’t written down, it didn’t happen.” Documentation provides proof of compliance, traceability, and accountability.

Audit findings in South Africa:

• Batch manufacturing records lacking operator signatures.
• SOPs that are outdated or missing version control.
• Deviations logged but never closed.
• Training registers without dates or instructor details.

Root causes:

• Heavy reliance on paper-based systems.
• Staff see record-keeping as secondary to production.
• Lack of real-time QA oversight.

Prevention strategies:

1. Implement electronic document management systems (EDMS) with audit trails.
2. Train operators that documentation is part of the job, not an administrative burden.
3. Schedule monthly internal documentation audits.
4. Empower QA to halt batch release if documentation is incomplete.

2. Inadequate Training and Competency Assessments

Why it matters: GMP requires personnel to be qualified for the tasks they perform. Training is not a one-off event but an ongoing process tied to evolving SOPs, technologies, and regulatory updates.

Audit findings:

• Personnel performing aseptic operations without current training.
• Training records showing attendance but no evidence of competence.
• Refresher training done only just before inspections.

Root causes:

• Treating training as a “tick-box exercise.”
• Lack of role-based training matrices.
• Resource constraints preventing continuous learning.

Prevention strategies:

1. Develop training matrices linked to job descriptions.
2. Assess competence with quizzes, observed tasks, and case scenarios.
3. Digitally track training completion and expiry dates.
4. Tie training outcomes to CAPAs and deviation investigations.

3. Weak Validation and Qualification

Why it matters: Validation ensures processes consistently deliver products meeting quality standards. Equipment and utilities must be qualified before use and re-qualified at defined intervals.

Audit findings:

• Water purification systems not validated for microbial limits.
• HVAC units without calibration records.
• Reused validation protocols that no longer reflect current practice.

Root causes:

• Validation is resource-intensive and often outsourced.
• Companies delay re-qualification to save costs.
• Inadequate internal review of vendor validation reports.

Prevention strategies:

1. Maintain a Master Validation Plan (MVP) updated annually.
2. Use risk-based prioritisation and validate critical utilities first.
3. Track re-qualification dates in a compliance calendar with automated alerts.
4. Always conduct internal QA review of vendor-provided protocols and reports.

4. Data Integrity Gaps

Why it matters: Data integrity underpins trust in both product quality and clinical trial outcomes. Regulators now treat it as a critical inspection focus area.

Audit findings:

• Back-dated entries in logbooks.
• Missing raw data from stability studies.
• Laboratory instruments without audit trails.
• Shared logins on electronic systems.

Root causes:

• Legacy paper systems dominate.
• Staff tidy up records after the fact.
• Lack of validated software systems.

Prevention strategies:

1. Train staff on ALCOA+ principles.
2. Move to validated digital systems with unique user access.
3. Conduct random monthly data integrity spot checks.
4. Enforce zero tolerance for retrospective data entry.

5. Inadequate Supplier Qualification

Why it matters: The quality of medicines depends on the quality of materials, APIs, and packaging components. Weak supplier controls expose companies to contamination and compliance risks.

Audit findings:

• Suppliers added without formal qualification.
• Missing technical agreements with key vendors.
• Lack of periodic supplier re-assessment.

Root causes:

• Procurement prioritises cost and timelines over quality.
• Small companies lack resources for audits.
• QA excluded from supplier approval decisions.

Prevention strategies:

1. Establish a supplier qualification SOP with clear risk categories.
2. Maintain an Approved Vendor List (AVL) updated quarterly.
3. Audit high-risk suppliers every two to three years.
4. Store supplier GMP declarations and Certificates of Analysis centrally.

6. Ineffective CAPA Management

Why it matters: Corrective and Preventive Actions (CAPAs) are the backbone of continuous improvement. Poor CAPA systems result in recurring deviations and erode regulatory confidence.

Audit findings:

• CAPAs closed without true root cause analysis.
• Same deviations reported across multiple audits.
• CAPA effectiveness checks missing.

Root causes:

• Pressure to close CAPAs quickly.
• Superficial fixes instead of systemic changes.

Prevention strategies:

1. Train teams in root cause tools.
2. Require senior QA or Responsible Pharmacist sign-off before closure.
3. Track CAPA effectiveness through follow-up audits.
4. Link CAPA metrics to management performance KPIs.

7. Housekeeping and Facility Maintenance

Why it matters: Facilities must be clean, controlled, and suitable for pharmaceutical production. Even minor housekeeping failures signal poor culture to regulators.

Audit findings:

• Dust accumulation in secondary packaging rooms.
• Damaged floors and peeling paint.
• Open drains near manufacturing areas.
• Pest control records incomplete.

Root causes:

• Understaffed facilities teams.
• Preventive maintenance often deferred.
• Lack of operator accountability for daily cleanliness.

Prevention strategies:

1. Apply 5S methodology.
2. Use a preventive maintenance schedule with digital alerts.
3. Train operators to own daily housekeeping tasks.
4. Conduct unannounced internal inspections monthly.

Building a Culture of Compliance

Preventing GMP failures is not just about fixing processes; it is about culture. In South Africa, companies that thrive under inspection embed quality into daily operations rather than scrambling before audits.

1. Leadership commitment – Responsible Pharmacists and executives must model GMP compliance.
2. Employee ownership – frontline operators empowered to report issues without fear.
3. Recognition and reward – celebrate inspection successes and quality improvements.

Conclusion

The seven recurring GMP audit findings – documentation, training, validation, data integrity, supplier qualification, CAPA management, and housekeeping – are preventable. By addressing them proactively, companies can reduce regulatory risk, strengthen partnerships with sponsors, and protect patients.

How GH Strategies Supports GMP Compliance

GH Strategies supports pharmaceutical manufacturers and clinical operations teams in building inspection-ready GMP systems aligned with SAHPRA expectations.

• GMP quality and compliance consulting for pharmaceutical companies
• SAHPRA inspection readiness and regulatory affairs consulting
• GMP training and capacity building for pharmaceutical teams
• Speak to GH Strategies about GMP audit readiness